Metizolam

Co-administration of metizolam with any opioid produces synergistic respiratory depression through complementary receptor mechanisms. This combination is the primary cause of benzodiazepine-involved fatalities. FDA boxed warnings exist for the opioid-benzodiazepine combination.

Alcohol and metizolam both act as GABA-A receptor positive allosteric modulators, producing additive CNS and respiratory depression. The combination substantially increases risk of respiratory failure, aspiration, and death.

Patients with pre-existing respiratory insufficiency (COPD, sleep apnea, neuromuscular respiratory compromise) face elevated risk of respiratory failure from benzodiazepine-induced respiratory depression, even at therapeutic doses.

Benzodiazepine-induced muscle relaxation may worsen symptoms of myasthenia gravis by further reducing neuromuscular transmission efficacy. This is a class-level contraindication for all GABA-A PAMs.

Individuals with a history of substance use disorder face elevated risk of dependence and compulsive use with benzodiazepine-class compounds. The combination of anxiolysis, amnesia, and impaired judgment creates conditions for rapid escalation.

Metizolam undergoes extensive hepatic metabolism (three hydroxylated metabolites identified via HLM incubation; only 0.3% excreted unchanged in urine). Severe hepatic impairment would reduce clearance, prolonging duration and intensifying effects unpredictably.

Benzodiazepines cross the placenta and are associated with neonatal withdrawal syndrome (floppy infant syndrome) and possible teratogenic effects. No metizolam-specific reproductive toxicity data exist.